Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol

• Main Authors: Olga B. Baltzersen (Author), Herbert Y. Meltzer (Author), Vibe G. Frokjaer (Author), Jayachandra M. Raghava (Author), Lone Baandrup (Author), Birgitte Fagerlund (Author), Henrik B.W. Larsson (Author), H. Christian Fibiger (Author), Birte Y. Glenthøj (Author), Gitte M. Knudsen (Author), Bjørn H. Ebdrup (Author)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2020-04-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

BackgroundAll current approved antipsychotic drugs against schizophrenia spectrum disorders share affinity for the dopamine receptor (D2R). However, up to one-third of these patients respond insufficiently, and in some cases, side-effects outweigh symptom reduction. Previous data have suggested that...